Nicholas S Britt
Overview
Explore the profile of Nicholas S Britt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Craddock V, Steere E, Harman H, Britt N
Antibiotics (Basel)
. 2023 Jun;
12(6).
PMID: 37370396
Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm...
2.
Britt N, Khader K, He T, Willson T, Effiong A, Timbrook T, et al.
Pharmacotherapy
. 2022 Dec;
43(1):24-34.
PMID: 36484553
Study Objective: Bloodstream infections (BSIs) are a significant cause of mortality. Use of a rapid multiplex polymerase chain reaction-based blood culture identification panel (BCID) may improve antimicrobial utilization and clinical...
3.
Mohan A, Agarwal S, Clauss M, Britt N, Dhillon N
Respir Res
. 2020 Jul;
21(1):175.
PMID: 32641036
The lung is the organ with the highest vascular density in the human body. It is therefore perceivable that the endothelium of the lung contributes significantly to the circulation of...
4.
Britt N, Hazlett D, Horvat R, Liesman R, Steed M
Int J Antimicrob Agents
. 2020 Jan;
55(4):105898.
PMID: 31931147
Vancomycin is commonly used to treat methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis (CF) lung disease. However, there are limited data to support the in vitro activity...
5.
Avery L, Kuti J, Weisser M, Egli A, Rybak M, Zasowski E, et al.
Int J Antimicrob Agents
. 2019 Jul;
54(3):346-350.
PMID: 31284042
Daptomycin is commonly prescribed in combination with other antibiotics for treatment of enterococcal bacteraemia. Whilst a free drug area under the concentration-time curve to minimum inhibitory concentration (fAUC/MIC) ratio >27.4...
6.
Avery L, Kuti J, Weisser M, Egli A, Rybak M, Zasowski E, et al.
Clin Infect Dis
. 2019 Feb;
69(5):903-904.
PMID: 30715199
No abstract available.
7.
Avery L, Kuti J, Weisser M, Egli A, Rybak M, Zasowski E, et al.
Clin Infect Dis
. 2018 Sep;
68(10):1650-1657.
PMID: 30188976
Background: Currently, there is debate over whether the daptomycin susceptibility breakpoint for enterococci (ie, minimum inhibitory concentration [MIC] ≤4 mg/L) is appropriate. In bacteremia, observational data support prescription of high...
8.
Roberts K, Shuster J, Britt N, Balsara K, Graetz T, Helwani M, et al.
ASAIO J
. 2018 May;
65(3):264-269.
PMID: 29750687
Few studies have evaluated the use of phosphodiesterase-5 inhibitors (PDE5-i) for right ventricular (RV) dysfunction after left ventricular assist device (LVAD) implantation. The study purpose was to examine the impact...
9.
Britt N, Ritchie D, Kollef M, Burnham C, Durkin M, Hampton N, et al.
Am J Infect Control
. 2018 May;
46(10):1092-1096.
PMID: 29706365
Background: Infections caused by carbapenem-resistant gram-negative bacilli are an emerging public health threat. However, there is a paucity of data examining comparative incidence rates, risk factors, and outcomes in this...
10.
Britt N, Ritchie D, Kollef M, Burnham C, Durkin M, Hampton N, et al.
Antimicrob Agents Chemother
. 2018 Jan;
62(4).
PMID: 29378722
In a retrospective analysis of 215 patients with carbapenem-resistant sepsis, we observed a significantly higher risk of mortality associated with respiratory tract infection (risk ratio [RR], 1.20; 95% confidence interval...